The FDA approved resmetirom for the treatment of adults with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis.
To better understand the relationship between cardiovascular disease and liver disease in individuals with HIV, researchers examined both traditional risk factors and HIV-specific risk factors of the...
The researchers set out to determine the mortality risk and complications associated with direct-acting antiviral treatment in patients with chronic hepatitis C.
Researchers identified the prevalence of non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), and non-alcoholic steatohepatitis (NASH) in individuals who are overweight or obese. ...
To better understand mortality trends within the United States, researchers examined the rate of death in people who died of alcohol-related liver disease.
The researchers examined the prevalence of steatosis, nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis in individuals with metabolically healthy obesity and metabolically abnormal obesity...
A research team has determined the risk factors for moderate to severe hepatic steatosis among patients with HIV by comparing the prevalence rates of hepatic steatosis among patients with HIV vs without...
Several biomarkers obtained through non-invasive means could help to predict the development of non-alcoholic fatty liver disease in patients living with HIV (PWH), according to recent research.
